Repligen CEO sends video to BioLife employees; merger expected to close in Q4 2026

BIOLIFE SOLUTIONS INC

Repligen CEO Olivier Loeillot recorded video message for BioLife employees on August 3, 2026.
Merger still requires regulatory and shareholder approvals; expected close in Q4 2026.
Repligen describes itself as a bioprocessing tools company with ~2,000 employees globally.
BioLife's CryoStor platform supports majority of US cell-based therapy trials.
Until close, BioLife and Repligen will operate as separate independent companies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.